<DOC>
	<DOCNO>NCT00930189</DOCNO>
	<brief_summary>The purpose study compare efficacy photodynamic therapy verteporfin ( PDT ) IVTA v triple therapy ( TT ) patient subfoveal choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) . The investigator design prospective , comparative , randomize , double blind , control study . 15 patient classic subfoveal choroidal neovascularization secondary age-related macular degeneration randomize . Triple therapy potentially offer new treatment modality choroidal neovascularization patient macular degeneration disease .</brief_summary>
	<brief_title>Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy , Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization</brief_title>
	<detailed_description>Purpose : To compare efficacy photodynamic therapy verteporfin ( PDT ) IVTA v triple therapy ( TT ) patient subfoveal choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) . Methods : Prospective , comparative , randomize , double blind , control study . 15 patient classic subfoveal choroidal neovascularization secondary age-related macular degeneration randomize . Group 1 : receive PDT follow 4 mg IVTA ( n=7 ) group 2 : TT ( triple Therapy ) PDT follow 4 mg IVTA + 0.5 mg Ranibizumab ( n=8 ) .The main outcome measure visual acuity ( VA ) , mean change lesion size , mean change foveal thickness , retreatment rate incidence severity adverse event . Results : At 6 month 5 7 patient ( 71.4 % ) group 1 8 8 patient ( 100 % ) group 2 lose few 15 letter ( P &lt; .001 ) . Three patient ( 37.5 % ) group 2 improvement 3 line . Lesion type , patient age , lesion size influence outcome , baseline VA statistically significant effect ( P =.006 ) . The median number treatment group one . The 28 % PDT-triamcinolone group 25 % triple therapy group increase intraocular pressure ( IOP ) require therapy . Progression development cataract observe 14.2 % PDT- IVTA group 12.5 % Triple therapy group . There case endophthalmitis . No cardiac cerebrovascular accident present . Conclusions : The combination PDT , intravitreal triamcinolone acetonide intravitreal ranibizumab safe treatment option neovascular AMD prevents considerable decrease VA . In patient seem superior combinated therapy PDT triamcinolone . Clinical Relevance : Triple therapy potentially offer new treatment modality choroidal neovascularization patient macular degeneration disease . :</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Subfoveal choroidal neovascularization ( CNV ) secondary agerelated macular degeneration ( AMD ) Any visual acuity Previous treatment Glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>age relate macular degeneration</keyword>
</DOC>